November 12, 2026
Mitotech to Present Two Posters on MT-1101, Its Oral Obesity Treatment Candidate, at ObesityWeek® 2026
October 05, 2026
Mitotech Highlights New MT-1101 Data Presented at Obesity Science & Innovation USA 2026
June 30, 2025
ADA 2025: Sensing a Shift in Obesity Care Industry
June 06, 2025
Mitotech to present at Obesity Science and Innovation 2025
November 15, 2024
Mitotech Presents New positive Animal Efficacy Data for MT-1101 in MASH Treatment at The 75th Liver Meeting
November 06, 2024
Mitotech Unveils Promising New Obesity Treatment Data on MT-1101 at ObesityWeek 2024
September 17, 2024
Mitotech Presents Promising Results in Friedreich’s Ataxia
April 29, 2024
Mitotech to Present at LSX World Congress
October 11, 2023
Mitotech CEO To Present At LSX Investival Showcase 2023
October 01, 2023
Mitotech COO To Present At Bio Investor Forum 2023
September 21, 2023
Mitotech CSO to present at Targeting Mitochondria 2023 Conference
October 13, 2022
Essex Biotechnology Secures Exclusive Rights in Mitotech’s lead candidate SkQ1 for Ophthalmology
February 24, 2022
Mitotech CSO to present at Mitochondria-Targeted Drug Development Summit
January 26, 2022
Mitotech to Host Key Opinion Leader Webinar on Visomitin®: A Potential Treatment for Dry Eye Disease
December 15, 2021
Mitotech granted Orphan Drug Designation by FDA for Visomitin® in LHON
May 06, 2021
Mitotech's focus on opthalmology discussed in Fierce Biotech publication
March 04, 2021
Mitotech CEO Natalia Perekhvatova to present at OIS Dry Eye Innovation Showcase 2021
February 26, 2021
Mitotech and Essex Bio-Technology announce positive results of VISTA-2 Phase 3 clinical study in Dry Eye Disease
February 01, 2021
Mitotech to present at LSX Congress 2021
January 11, 2021
Mitotech S.A. To Present at Biotech Showcase Digital 2021 Conference
October 23, 2020
Mitotech to present in Eyecelerator's Retina Livestream organized by AAO and ASCRS
August 25, 2020
Mitotech and Essex Bio-Technology Complete Enrollment in VISTA-2 – a pivotal Phase 3 Clinical Study of SkQ1 for Dry Eye Disease
December 12, 2019
Mitotech and Essex Bio-Technology Announce Enrollment in VISTA-2 - a pivotal Phase 3 Clinical Study of SkQ1 for Dry Eye Disease
October 29, 2018
Mitotech Completes First Patient Visit in VISTA-1 - Phase 2b/3 Clinical Study of SkQ1 for Dry Eye Disease
October 23, 2018
Mitotech Initiates Phase 2b/3 Clinical Trial of SkQ1 Ophthalmic Solution in Patients with Dry Eye Disease in a Co-Development Effort with Essex Bio-Technology
July 19, 2018
Mitotech partners with Essex Bio-Technology for a late-stage clinical program in Dry Eye Disease
October 24, 2017
Mitotech announces new Dry Eye data set supporting SkQ1's novel mechanism of action
April 26, 2017
Mitotech's SkQ1 improved visual acuity in Leber's Hereditary Optic Neuropathy (LHON) patients
April 20, 2017
Mitotech's SkQ1 and its potential for treating age-related disorders discussed in Fierce Biotech publication
March 21, 2017
Mitotech's lead compound significantly increased lifespan of rapidly aging mice
February 10, 2017
Mitotech discusses SkQ1 and Dry Eye Disease in a recent Fierce Biotech article
February 07, 2017
Mitotech will attend the Biotech and Money conference in London, Feb 7-8, 2017
January 20, 2017
Mitotech S.A. Developing a Dry Eye Treatment has been Granted Two U.S. Patents for Pharmaceutical Formulations
September 09, 2016
Mitotech S.A. is granted a patent in anti-aging
July 27, 2016
Mitotech S.A. announces its Ophthalmic Scientific Advisory Board
March 20, 2016
Oxidative stress and dry eye in Review of Ophthalmology
March 01, 2016
Mitotech S.A. to present at ARVO 2016
February 05, 2016
Mitotech CEO to present at the annual BIO CEO and Investor Conference 2016
January 25, 2016
Mitotech S.A. to initiate its first clinical study of a systemic formulation of SkQ1
January 10, 2016
Results of SkQ1 U.S. Phase 2 Clinical Study in Patients with Dry Eye Syndrome published in Advances in Therapy journal
December 27, 2015
Results of Mitotech's Multicenter Clinical Study in Patients with Dry Eye Syndrome published in Advances in Therapy journal
October 16, 2015
Mitotech S.A. to present at the 2015 Sofinnova Japan Biopharma Partnering Conference
May 03, 2015
Mitotech's posters at ARVO 2015 in Denver, May 3-7
April 23, 2015
Mitotech Announces Phase 2 Data Showing Positive Effect of SkQ1 in Patients with Dry Eye Syndrome
April 21, 2014
Mitotech S.A. announces the initiation of Phase II clinical trial in Dry Eye Patients Utilizing the Controlled Adverse Environment
May 14, 2013
Mitotech completes series of uveitis studies
December 09, 2012
Mitotech's posters at ARVO 2015 in Denver, May 3-7
January 17, 2012
Mitotech initiated pre-clinical program for SkQ1 compound in the U.S.